JP5450434B2 - 関節炎の治療方法 - Google Patents
関節炎の治療方法 Download PDFInfo
- Publication number
- JP5450434B2 JP5450434B2 JP2010534194A JP2010534194A JP5450434B2 JP 5450434 B2 JP5450434 B2 JP 5450434B2 JP 2010534194 A JP2010534194 A JP 2010534194A JP 2010534194 A JP2010534194 A JP 2010534194A JP 5450434 B2 JP5450434 B2 JP 5450434B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- benzoyl
- phenylsulfanyl
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010003246 arthritis Diseases 0.000 title claims description 18
- -1 4- (4-((4'-chloro (1,1'-biphenyl) -2-yl) methyl) piperazin-1-yl) benzoyl Chemical group 0.000 claims description 513
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 352
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 56
- 241000124008 Mammalia Species 0.000 claims description 17
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 240
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 159
- 150000001875 compounds Chemical class 0.000 description 50
- 150000002390 heteroarenes Chemical class 0.000 description 42
- 150000001924 cycloalkanes Chemical class 0.000 description 41
- 150000001925 cycloalkenes Chemical class 0.000 description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 34
- 125000000217 alkyl group Chemical group 0.000 description 31
- 229910052794 bromium Inorganic materials 0.000 description 28
- 229910052801 chlorine Inorganic materials 0.000 description 28
- 229910052731 fluorine Inorganic materials 0.000 description 28
- 229910052740 iodine Inorganic materials 0.000 description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
- 125000001072 heteroaryl group Chemical group 0.000 description 25
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 24
- 229910052717 sulfur Inorganic materials 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 14
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 125000000392 cycloalkenyl group Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Chemical class 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000019483 Peanut oil Nutrition 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000312 peanut oil Substances 0.000 description 5
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 108020003519 protein disulfide isomerase Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- BVCSIOBITBWJKT-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 BVCSIOBITBWJKT-DIPNUNPCSA-N 0.000 description 2
- FSVNUMUJCUAQKS-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]-4-methoxypiperidin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN3CCOCC3)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=C(Cl)C=C1 FSVNUMUJCUAQKS-KXQOOQHDSA-N 0.000 description 2
- FHAVNLCQMRZULW-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(diethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(CC)CC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 FHAVNLCQMRZULW-DIPNUNPCSA-N 0.000 description 2
- ITFHGSGWNBNFCM-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 ITFHGSGWNBNFCM-DIPNUNPCSA-N 0.000 description 2
- HPLNQCPCUACXLM-DHUJRADRSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2s)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-DHUJRADRSA-N 0.000 description 2
- PQPAZFYAWSKVQT-UUWRZZSWSA-N 5-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzoic acid Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1C(O)=O)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 PQPAZFYAWSKVQT-UUWRZZSWSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 description 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- PCCPERGCFKIYIS-AWEZNQCLSA-N daxalipram Chemical compound C1=C(OC)C(OCCC)=CC([C@@]2(C)OC(=O)NC2)=C1 PCCPERGCFKIYIS-AWEZNQCLSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- UHSZDQFSPDAFAH-PSXMRANNSA-N n-[4-[[(2r)-4-(azetidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCC1 UHSZDQFSPDAFAH-PSXMRANNSA-N 0.000 description 2
- TYJZZFVFAWMPRZ-PGUFJCEWSA-N n-[4-[[(2r)-6-amino-1-phenylsulfanylhexan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCCCN)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 TYJZZFVFAWMPRZ-PGUFJCEWSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SFGFYNXPJMOUHK-PKAFTLKUSA-N (2r)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-n-[(2r)-1-[[(2r)-1-[[(2r)-1-[[(2r)-1-[[(2r)-1-[[(2r)-1-[[2-[[(2r)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohe Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)NCC(=O)N[C@@H](C(N)=O)CC1=CC=C(O)C=C1 SFGFYNXPJMOUHK-PKAFTLKUSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- DRSJLVGDSNWQBI-SFHVURJKSA-N (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(2,6-dimethoxyphenyl)phenyl]propanoic acid Chemical compound COC1=CC=CC(OC)=C1C(C=C1)=CC=C1C[C@@H](C(O)=O)NC(=O)C1=C(Cl)C=CC=C1Cl DRSJLVGDSNWQBI-SFHVURJKSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 description 1
- ULTMDKZXHAEJJP-JGCGQSQUSA-N (3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutanoic acid Chemical compound C([C@@H](CC(=O)O)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ULTMDKZXHAEJJP-JGCGQSQUSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- IRELROQHIPLASX-SEYXRHQNSA-N (z)-2-cyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]hept-2-en-6-ynamide Chemical compound C#CCCC(/O)=C(\C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 IRELROQHIPLASX-SEYXRHQNSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- TVCVZPPTRJJNOP-UHFFFAOYSA-N 1,2-dihydropyridine-2-carboxylic acid Chemical compound OC(=O)C1NC=CC=C1 TVCVZPPTRJJNOP-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- JXAQDVYHEGKOSZ-KXQOOQHDSA-N 1-[(3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutyl]-n-hydroxypiperidine-4-carboxamide Chemical compound C1CC(C(=O)NO)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 JXAQDVYHEGKOSZ-KXQOOQHDSA-N 0.000 description 1
- IEMUECOTLKXVOF-PSXMRANNSA-N 1-[(3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutyl]azetidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 IEMUECOTLKXVOF-PSXMRANNSA-N 0.000 description 1
- QBXIGOHEWAHXSP-KXQOOQHDSA-N 1-[(3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 QBXIGOHEWAHXSP-KXQOOQHDSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonic acid Chemical class CC1=CC(C)=C(S(O)(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-N 0.000 description 1
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- AMNKRBRQQAMACZ-UHFFFAOYSA-N 2-[(4-ethynyl-2-fluorophenyl)amino]-3,4-difluoro-n-(2-hydroxyethoxy)benzamide Chemical compound OCCONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(C#C)C=C1F AMNKRBRQQAMACZ-UHFFFAOYSA-N 0.000 description 1
- RQVKVJIRFKVPBF-VWLOTQADSA-N 2-[[(2s)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C([C@H](N)CNC=1N(C(C(C=2C=C3C=CC=CC3=CC=2)=C(C=2C=CN=CC=2)N=1)=O)C)C1=CC=CC=C1 RQVKVJIRFKVPBF-VWLOTQADSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PDAOEDPQIGLIPB-PGUFJCEWSA-N 3,5-difluoro-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=C(F)C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=C(F)C=1)CSC=1C=CC=CC=1)CN1CCOCC1 PDAOEDPQIGLIPB-PGUFJCEWSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- WCMSFBRREKZZFL-UHFFFAOYSA-N 3-cyclohexen-1-yl-Benzene Chemical compound C1CCCC(C=2C=CC=CC=2)=C1 WCMSFBRREKZZFL-UHFFFAOYSA-N 0.000 description 1
- ZISNQBZEFLWSBG-PSXMRANNSA-N 3-fluoro-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=C(F)C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 ZISNQBZEFLWSBG-PSXMRANNSA-N 0.000 description 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- ZFMGZICVNJWTQY-DIPNUNPCSA-N 4-[1-[[2-(4-chlorophenyl)phenyl]methyl]-3,6-dihydro-2h-pyridin-4-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)C=1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC=1)[N+]([O-])=O)SC1=CC=CC=C1 ZFMGZICVNJWTQY-DIPNUNPCSA-N 0.000 description 1
- OZLTZCBTYAMLBH-LDLOPFEMSA-N 4-[1-[[2-(4-chlorophenyl)phenyl]methyl]-3,6-dihydro-2h-pyridin-4-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)C=1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 OZLTZCBTYAMLBH-LDLOPFEMSA-N 0.000 description 1
- BBSTVGMWTWVAHI-LDLOPFEMSA-N 4-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)C1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 BBSTVGMWTWVAHI-LDLOPFEMSA-N 0.000 description 1
- YHABPKDOYZAGLC-GDLZYMKVSA-N 4-[4-[(2-bromocyclohexen-1-yl)methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2Br)CC1)[N+]([O-])=O)SC1=CC=CC=C1 YHABPKDOYZAGLC-GDLZYMKVSA-N 0.000 description 1
- UXOWBBIPPFGAAL-MUUNZHRXSA-N 4-[4-[(2-bromocyclopenten-1-yl)methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCC=2Br)CC1)[N+]([O-])=O)SC1=CC=CC=C1 UXOWBBIPPFGAAL-MUUNZHRXSA-N 0.000 description 1
- TXEPPGZBOFIRIR-PGUFJCEWSA-N 4-[4-[(2-cyclohexylphenyl)methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C2CCCCC2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 TXEPPGZBOFIRIR-PGUFJCEWSA-N 0.000 description 1
- HMMXEILBJYEQDZ-PGUFJCEWSA-N 4-[4-[1-[2-(4-chlorophenyl)phenyl]cyclopropyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC1)C1(CC1)C=1C(=CC=CC=1)C=1C=CC(Cl)=CC=1)[N+]([O-])=O)SC1=CC=CC=C1 HMMXEILBJYEQDZ-PGUFJCEWSA-N 0.000 description 1
- RMUNYJUAFSZGPE-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC(C)(C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OCCN(C)C)CC1=CC=CC=C1C1=CC=CC=C1 RMUNYJUAFSZGPE-UHFFFAOYSA-N 0.000 description 1
- CITNYTOCOIBNCS-UUWRZZSWSA-N 4-[4-[2-[4-(dimethylamino)phenyl]benzoyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC1)C(=O)C=1C(=CC=CC=1)C=1C=CC(=CC=1)N(C)C)[N+]([O-])=O)SC1=CC=CC=C1 CITNYTOCOIBNCS-UUWRZZSWSA-N 0.000 description 1
- YXZNYISNAVCSLM-SSEXGKCCSA-N 4-[4-[3-(dimethylamino)benzoyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC1)C(=O)C=1C=C(C=CC=1)N(C)C)[N+]([O-])=O)SC1=CC=CC=C1 YXZNYISNAVCSLM-SSEXGKCCSA-N 0.000 description 1
- DHKFVDOGILWSBK-KXQOOQHDSA-N 4-[4-[[1-(4-chlorophenyl)naphthalen-2-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=C3C=CC=CC3=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 DHKFVDOGILWSBK-KXQOOQHDSA-N 0.000 description 1
- XICBEJRSMULUDD-RRHRGVEJSA-N 4-[4-[[1-(4-chlorophenyl)naphthalen-2-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=C3C=CC=CC3=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 XICBEJRSMULUDD-RRHRGVEJSA-N 0.000 description 1
- NHFBVFONRHKZKW-UUWRZZSWSA-N 4-[4-[[2-(1,3-benzodioxol-5-yl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=C3OCOC3=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 NHFBVFONRHKZKW-UUWRZZSWSA-N 0.000 description 1
- IEFLPCZOZWFDBZ-DIPNUNPCSA-N 4-[4-[[2-(1,3-dihydroisoindol-2-yl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)N2CC3=CC=CC=C3C2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 IEFLPCZOZWFDBZ-DIPNUNPCSA-N 0.000 description 1
- OEKZTCJBKTUJGA-PGUFJCEWSA-N 4-[4-[[2-(1-benzofuran-2-yl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2OC3=CC=CC=C3C=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 OEKZTCJBKTUJGA-PGUFJCEWSA-N 0.000 description 1
- FGLAXDFRKOSFJD-MGBGTMOVSA-N 4-[4-[[2-(2,4-dichlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C(=CC(Cl)=CC=2)Cl)CC1)[N+]([O-])=O)SC1=CC=CC=C1 FGLAXDFRKOSFJD-MGBGTMOVSA-N 0.000 description 1
- RWYMMRYSBJUSDO-MGBGTMOVSA-N 4-[4-[[2-(2,4-difluorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C(=CC(F)=CC=2)F)CC1)[N+]([O-])=O)SC1=CC=CC=C1 RWYMMRYSBJUSDO-MGBGTMOVSA-N 0.000 description 1
- FWJCVFIDEYATTJ-MGBGTMOVSA-N 4-[4-[[2-(2-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C(=CC=CC=2)Cl)CC1)[N+]([O-])=O)SC1=CC=CC=C1 FWJCVFIDEYATTJ-MGBGTMOVSA-N 0.000 description 1
- RVGNMGSFNRBBJK-MGBGTMOVSA-N 4-[4-[[2-(3,4-dichlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 RVGNMGSFNRBBJK-MGBGTMOVSA-N 0.000 description 1
- YIZHZCXDMHQFLC-PGUFJCEWSA-N 4-[4-[[2-(3-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=C(Cl)C=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 YIZHZCXDMHQFLC-PGUFJCEWSA-N 0.000 description 1
- INTDSHFPTWLAMR-PGUFJCEWSA-N 4-[4-[[2-(4-chloro-2-methylphenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C(=CC(Cl)=CC=2)C)CC1)[N+]([O-])=O)SC1=CC=CC=C1 INTDSHFPTWLAMR-PGUFJCEWSA-N 0.000 description 1
- NBMKOQKSMOMHKB-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CC(C)(C)CCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 NBMKOQKSMOMHKB-PSXMRANNSA-N 0.000 description 1
- DELXKQUNQDVDIA-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+]([O-])=O)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 DELXKQUNQDVDIA-KXQOOQHDSA-N 0.000 description 1
- YBOIRUPCORJBCY-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)-5-fluorophenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=C(F)C=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 YBOIRUPCORJBCY-PGUFJCEWSA-N 0.000 description 1
- SGDQZHZDGVFNDM-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)cyclohepten-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 SGDQZHZDGVFNDM-PSXMRANNSA-N 0.000 description 1
- SRQDOEOSPBMZKV-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)cyclohepten-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCCC=2C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 SRQDOEOSPBMZKV-KXQOOQHDSA-N 0.000 description 1
- NSNNTKKRDILGBB-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(diethylamino)-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CN(CC)CC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 NSNNTKKRDILGBB-PSXMRANNSA-N 0.000 description 1
- ZWMRMJHWCLYXDF-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(dimethylamino)-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ZWMRMJHWCLYXDF-UUWRZZSWSA-N 0.000 description 1
- KITUCOWQHHVVBL-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-morpholin-4-yl-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)CN1CCOCC1)SC1=CC=CC=C1 KITUCOWQHHVVBL-PSXMRANNSA-N 0.000 description 1
- SAKNKRHWDZRDEQ-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(diethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(CC)CC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 SAKNKRHWDZRDEQ-DIPNUNPCSA-N 0.000 description 1
- IBLRHIQQGLQOIC-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 IBLRHIQQGLQOIC-PGUFJCEWSA-N 0.000 description 1
- HFEHKGRVDWPATL-LDLOPFEMSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[di(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C(C)C)C(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HFEHKGRVDWPATL-LDLOPFEMSA-N 0.000 description 1
- XCSUGPMCFCIURZ-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[methyl(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 XCSUGPMCFCIURZ-DIPNUNPCSA-N 0.000 description 1
- XHJJDOWOWIVDLG-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)cyclopenten-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 XHJJDOWOWIVDLG-UUWRZZSWSA-N 0.000 description 1
- MZFOFWINHFIDFF-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]-4-methoxypiperidin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=C(Cl)C=C1 MZFOFWINHFIDFF-PSXMRANNSA-N 0.000 description 1
- BABGASIKJKFZSO-LVBDYELDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]cyclohexen-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)C=1CCC(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC=1)[N+]([O-])=O)SC1=CC=CC=C1 BABGASIKJKFZSO-LVBDYELDSA-N 0.000 description 1
- VMGORENNZHNRHB-RUPAOVHOSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]cyclohexen-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)C=1CCC(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 VMGORENNZHNRHB-RUPAOVHOSA-N 0.000 description 1
- HUHAEUZLTJSJAY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[1-(2-phenylsulfanylethyl)benzimidazol-5-yl]sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3N=CN(CCSC=4C=CC=CC=4)C3=CC=2)CC1 HUHAEUZLTJSJAY-UHFFFAOYSA-N 0.000 description 1
- KGPOVMZKWZQOBM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[1-(2-phenylsulfanylethyl)benzotriazol-5-yl]sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3N=NN(CCSC=4C=CC=CC=4)C3=CC=2)CC1 KGPOVMZKWZQOBM-UHFFFAOYSA-N 0.000 description 1
- ZNOPHVCRZHBXEY-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[1-[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]benzimidazol-5-yl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)N1C2=CC=C(C=C2N=C1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 ZNOPHVCRZHBXEY-DIPNUNPCSA-N 0.000 description 1
- DYGBQCABFJTICT-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[1-[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]benzotriazol-5-yl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)N1C2=CC=C(C=C2N=N1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 DYGBQCABFJTICT-PSXMRANNSA-N 0.000 description 1
- ZEFVDSMCBBQNEO-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[(2r)-1-phenylsulfanyl-4-(propan-2-ylamino)butan-2-yl]amino]phenyl]sulfonylbenzamide Chemical compound C([C@@H](CCNC(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ZEFVDSMCBBQNEO-PSXMRANNSA-N 0.000 description 1
- VPRLYBHEAAXGDJ-MUUNZHRXSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[(2r)-1-phenylsulfanylpropan-2-yl]amino]phenyl]sulfonylbenzamide Chemical compound C([C@@H](C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 VPRLYBHEAAXGDJ-MUUNZHRXSA-N 0.000 description 1
- SQAMVZPHTXUCLR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCC1CCCCC1 SQAMVZPHTXUCLR-UHFFFAOYSA-N 0.000 description 1
- IZNNGVLJDKUVEC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(1-methyl-4-phenylsulfanylpyrrolidin-3-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=CC=CC=1SC1CN(C)CC1NC(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 IZNNGVLJDKUVEC-UHFFFAOYSA-N 0.000 description 1
- ADJAPRGSLCJMDA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-pyrimidin-2-ylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=NC=CC=N1 ADJAPRGSLCJMDA-UHFFFAOYSA-N 0.000 description 1
- TTXSYIBMYHALFP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-thiophen-2-ylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CS1 TTXSYIBMYHALFP-UHFFFAOYSA-N 0.000 description 1
- GBTGUGZQATYUEP-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]oxy-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)OC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 GBTGUGZQATYUEP-PSXMRANNSA-N 0.000 description 1
- IFOMSDVAVXDCFZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(4-methoxycyclohexyl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CC(OC)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1[N+]([O-])=O IFOMSDVAVXDCFZ-UHFFFAOYSA-N 0.000 description 1
- IFSWWBCZOHDHOY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[2-[(4-methyl-1,3-thiazol-2-yl)sulfanyl]ethylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound CC1=CSC(SCCNC=2C(=CC(=CC=2)S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)[N+]([O-])=O)=N1 IFSWWBCZOHDHOY-UHFFFAOYSA-N 0.000 description 1
- XIPKFWPTVKMVSZ-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(4-chlorophenyl)sulfanyl-4-morpholin-4-ylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC(Cl)=CC=1)CN1CCOCC1 XIPKFWPTVKMVSZ-DIPNUNPCSA-N 0.000 description 1
- VCRRHGIOFGLZDE-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(4-fluorophenyl)sulfanyl-4-morpholin-4-ylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC(F)=CC=1)CN1CCOCC1 VCRRHGIOFGLZDE-DIPNUNPCSA-N 0.000 description 1
- KTZSZVFHLHUDCO-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(4-methoxyphenyl)sulfanyl-4-morpholin-4-ylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=CC(OC)=CC=C1SC[C@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CCN1CCOCC1 KTZSZVFHLHUDCO-DIPNUNPCSA-N 0.000 description 1
- WDGNXIBZIXLEQZ-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(4-methylphenyl)sulfanyl-4-morpholin-4-ylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=CC(C)=CC=C1SC[C@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CCN1CCOCC1 WDGNXIBZIXLEQZ-KXQOOQHDSA-N 0.000 description 1
- NQMUBZIIVJEADU-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(diethylamino)-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CN(CC)CC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 NQMUBZIIVJEADU-PSXMRANNSA-N 0.000 description 1
- WBWKHKSSCVDDEQ-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-(dimethylamino)-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 WBWKHKSSCVDDEQ-UUWRZZSWSA-N 0.000 description 1
- RQCQCMDMOFDYMS-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-[2-(dimethylamino)ethoxy]-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](COCCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 RQCQCMDMOFDYMS-PSXMRANNSA-N 0.000 description 1
- ROQWGBPGCFNWRP-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1-morpholin-4-yl-3-phenylsulfanylpropan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CN1CCOCC1)SC1=CC=CC=C1 ROQWGBPGCFNWRP-PSXMRANNSA-N 0.000 description 1
- IRPHKLOZNNOIMB-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(2,2-difluoroethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCNCC(F)F)NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 IRPHKLOZNNOIMB-UUWRZZSWSA-N 0.000 description 1
- SMNJFEYTAXVYRY-YNEWLZTQSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(2,5-dimethylpyrrolidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound CC1CCC(C)N1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 SMNJFEYTAXVYRY-YNEWLZTQSA-N 0.000 description 1
- QDIGWNZTAIIIAQ-IHVSBJKJSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(2,6-dimethylpiperidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound CC1CCCC(C)N1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 QDIGWNZTAIIIAQ-IHVSBJKJSA-N 0.000 description 1
- YIGBXROPRYUQMO-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(2-fluoroethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCNCCF)NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 YIGBXROPRYUQMO-PGUFJCEWSA-N 0.000 description 1
- XPVHKNXQINKLKS-LDLOPFEMSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(2-morpholin-4-ylethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CNCCN1CCOCC1 XPVHKNXQINKLKS-LDLOPFEMSA-N 0.000 description 1
- CDUDDESXRBWVDB-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(3-hydroxyazetidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1C(O)CN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 CDUDDESXRBWVDB-PGUFJCEWSA-N 0.000 description 1
- DDXPIJUJWPULED-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(4-hydroxypiperidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CC(O)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 DDXPIJUJWPULED-DIPNUNPCSA-N 0.000 description 1
- RUWBXIHSGCPLRQ-LDLOPFEMSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(4-methoxyiminopiperidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CC(=NOC)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 RUWBXIHSGCPLRQ-LDLOPFEMSA-N 0.000 description 1
- GAQRFXRNPKHGKM-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(4-methylpiperazin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 GAQRFXRNPKHGKM-KXQOOQHDSA-N 0.000 description 1
- CNPKADPOAGXMFH-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(4-methylpiperazin-1-yl)-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1C(=O)C[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 CNPKADPOAGXMFH-DIPNUNPCSA-N 0.000 description 1
- IQZYBVFARZNMRP-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(cyclopropylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CNC1CC1 IQZYBVFARZNMRP-PSXMRANNSA-N 0.000 description 1
- ROZLGEDUISLTCX-JGCGQSQUSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-(1,3-thiazol-2-ylsulfanyl)butan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=NC=CS1 ROZLGEDUISLTCX-JGCGQSQUSA-N 0.000 description 1
- UDUZXLMFSRLWPN-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-(4-fluorophenyl)sulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=C(F)C=C1 UDUZXLMFSRLWPN-PGUFJCEWSA-N 0.000 description 1
- HYJVATOFXSVCSN-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-2,5-difluorophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=C(F)C=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)F)SC1=CC=CC=C1 HYJVATOFXSVCSN-UUWRZZSWSA-N 0.000 description 1
- KXNOBYHDFIQNSV-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3,5-difluorophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1F)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)F)SC1=CC=CC=C1 KXNOBYHDFIQNSV-UUWRZZSWSA-N 0.000 description 1
- ATYKADVXGKGSNM-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-fluorophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)F)SC1=CC=CC=C1 ATYKADVXGKGSNM-PGUFJCEWSA-N 0.000 description 1
- NTAMUMHGDBRIOA-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-methylphenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)C)SC1=CC=CC=C1 NTAMUMHGDBRIOA-DIPNUNPCSA-N 0.000 description 1
- RTYVOTTUGUNQFO-MGBGTMOVSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-2-fluorobenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C(=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)F)[N+]([O-])=O)SC1=CC=CC=C1 RTYVOTTUGUNQFO-MGBGTMOVSA-N 0.000 description 1
- PQFBLSQPCTWBLW-MGBGTMOVSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-thiophen-2-ylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CS1 PQFBLSQPCTWBLW-MGBGTMOVSA-N 0.000 description 1
- CCTJFFBWLCDEPU-LDLOPFEMSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dipropylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(CCC)CCC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 CCTJFFBWLCDEPU-LDLOPFEMSA-N 0.000 description 1
- LODNDPZEAGVIBG-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(methylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCNC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LODNDPZEAGVIBG-UUWRZZSWSA-N 0.000 description 1
- QWBVJOISVDHUST-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(morpholin-4-ylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CNN1CCOCC1 QWBVJOISVDHUST-DIPNUNPCSA-N 0.000 description 1
- VUYQIFBWYSAEAL-XXKIVBBDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[(3r)-3-hydroxypyrrolidin-1-yl]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1[C@H](O)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 VUYQIFBWYSAEAL-XXKIVBBDSA-N 0.000 description 1
- ORIJVCOUQSISIK-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[2-hydroxyethyl(methyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(CCO)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ORIJVCOUQSISIK-PSXMRANNSA-N 0.000 description 1
- UAYYNGKKJGCMOU-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[cyclopropyl(methyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C1CC1)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 UAYYNGKKJGCMOU-PSXMRANNSA-N 0.000 description 1
- LOIHLUSLKLTVMO-LDLOPFEMSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[di(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C(C)C)C(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LOIHLUSLKLTVMO-LDLOPFEMSA-N 0.000 description 1
- ORTVYOYVDWOCIC-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[ethyl(2,2,2-trifluoroethyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(CC)CC(F)(F)F)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ORTVYOYVDWOCIC-PSXMRANNSA-N 0.000 description 1
- UTNWKHHOEGYRHB-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[methyl(2,2,2-trifluoroethyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)CC(F)(F)F)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 UTNWKHHOEGYRHB-PGUFJCEWSA-N 0.000 description 1
- WJIVIIWAMTWFBU-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[methyl(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 WJIVIIWAMTWFBU-DIPNUNPCSA-N 0.000 description 1
- JVIZEUDWXDPMLE-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[methyl(pyridin-4-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C=1C=CN=CC=1)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 JVIZEUDWXDPMLE-KXQOOQHDSA-N 0.000 description 1
- JUXOVBZRMBOOCV-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-cyano-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCC#N)NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 JUXOVBZRMBOOCV-UUWRZZSWSA-N 0.000 description 1
- MZEUKCAXFYQIDH-MGBGTMOVSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-hydroxy-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCO)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 MZEUKCAXFYQIDH-MGBGTMOVSA-N 0.000 description 1
- MDADPMGUPVXMHW-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-imidazol-1-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1C=CN=C1 MDADPMGUPVXMHW-PSXMRANNSA-N 0.000 description 1
- HXHGRFIQDFHNJL-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-(1,3-thiazol-2-ylsulfanyl)butan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1SC=CN=1)CN1CCOCC1 HXHGRFIQDFHNJL-UUWRZZSWSA-N 0.000 description 1
- UBHFAHXPIBNCDW-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CC(=O)N1CCOCC1)SC1=CC=CC=C1 UBHFAHXPIBNCDW-PSXMRANNSA-N 0.000 description 1
- NSQDLSIEAWDGAY-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-4-oxo-1-thiophen-2-ylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CC(=O)N1CCOCC1)SC1=CC=CS1 NSQDLSIEAWDGAY-UUWRZZSWSA-N 0.000 description 1
- LNUBIQRVTUDVPR-LDLOPFEMSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-5-(4-methylpiperazin-1-yl)-1-phenylsulfanylpentan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1CCC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 LNUBIQRVTUDVPR-LDLOPFEMSA-N 0.000 description 1
- LJWNDFGTRMGICJ-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-6-(methanesulfonamido)-1-phenylsulfanylhexan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCCCNS(=O)(=O)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LJWNDFGTRMGICJ-PSXMRANNSA-N 0.000 description 1
- GHSKMLGVXKTGGZ-QLKFWGTOSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2s)-4-(dimethylamino)-2-methyl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@](C)(CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 GHSKMLGVXKTGGZ-QLKFWGTOSA-N 0.000 description 1
- LWHMFWQPHKVIFL-DHUJRADRSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2s)-4-methyl-1-phenylsulfanylpentan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](CC(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LWHMFWQPHKVIFL-DHUJRADRSA-N 0.000 description 1
- RAPGCUWJNBHKDC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[1-[(2-methylfuran-3-yl)sulfanylmethyl]cyclopentyl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound O1C=CC(SCC2(CCCC2)NC=2C(=CC(=CC=2)S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)[N+]([O-])=O)=C1C RAPGCUWJNBHKDC-UHFFFAOYSA-N 0.000 description 1
- ZEFVUWLHJINFIV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[2-methyl-1-(1,3-thiazol-2-ylsulfanyl)propan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=NC=CS1 ZEFVUWLHJINFIV-UHFFFAOYSA-N 0.000 description 1
- BGXAAKQJHNMRHC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[cyclohexylmethyl(propyl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1N(CCC)CC1CCCCC1 BGXAAKQJHNMRHC-UHFFFAOYSA-N 0.000 description 1
- JRUODMAVBYAKIM-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCC(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 JRUODMAVBYAKIM-PSXMRANNSA-N 0.000 description 1
- GPALRAPSMBUUGA-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCC(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 GPALRAPSMBUUGA-KXQOOQHDSA-N 0.000 description 1
- DFTPNTVFJGRUKF-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)pyridin-3-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=NC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 DFTPNTVFJGRUKF-PSXMRANNSA-N 0.000 description 1
- WJBKDQOUHSGLJT-DIPNUNPCSA-N 4-[4-[[2-(4-fluorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(F)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 WJBKDQOUHSGLJT-DIPNUNPCSA-N 0.000 description 1
- JEWSYLJMXCSBME-DIPNUNPCSA-N 4-[4-[[2-(4-methylsulfonylphenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN3CCOCC3)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 JEWSYLJMXCSBME-DIPNUNPCSA-N 0.000 description 1
- XZHAKMPFYAUEJE-PSXMRANNSA-N 4-[4-[[2-(benzylamino)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)NCC=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 XZHAKMPFYAUEJE-PSXMRANNSA-N 0.000 description 1
- YLMURQOFHMQRRU-PGUFJCEWSA-N 4-[4-[[2-(cyclohexylamino)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)NC2CCCCC2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 YLMURQOFHMQRRU-PGUFJCEWSA-N 0.000 description 1
- CNCWFIWLMDMGOG-PSXMRANNSA-N 4-[4-[[2-[4-(dimethylamino)phenyl]phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(=CC=2)N(C)C)CC1)[N+]([O-])=O)SC1=CC=CC=C1 CNCWFIWLMDMGOG-PSXMRANNSA-N 0.000 description 1
- PMUFVHDUTGBHLJ-PGUFJCEWSA-N 4-[4-[[2-[4-(dimethylamino)phenyl]pyridin-3-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=NC=CC=2)C=2C=CC(=CC=2)N(C)C)CC1)[N+]([O-])=O)SC1=CC=CC=C1 PMUFVHDUTGBHLJ-PGUFJCEWSA-N 0.000 description 1
- OCYXKXWZWZZVQH-UHFFFAOYSA-N 4-[4-[[2-[4-[2-(dimethylamino)ethoxy]phenyl]phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC(C)(C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 OCYXKXWZWZZVQH-UHFFFAOYSA-N 0.000 description 1
- AOWMWGRHMRLLBL-UUWRZZSWSA-N 4-[4-[[3-(4-chlorophenyl)pyridin-4-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CN=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 AOWMWGRHMRLLBL-UUWRZZSWSA-N 0.000 description 1
- CGRQZLLZTBOPHS-UUWRZZSWSA-N 4-[4-[[4-(4-chlorophenyl)-3,6-dihydro-2h-pyran-5-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2COCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 CGRQZLLZTBOPHS-UUWRZZSWSA-N 0.000 description 1
- HSNFUNXDMCDUPQ-UUWRZZSWSA-N 4-[4-[[4-(4-chlorophenyl)pyridin-3-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=NC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HSNFUNXDMCDUPQ-UUWRZZSWSA-N 0.000 description 1
- GNHIIXOWHUCNIH-PSXMRANNSA-N 4-[4-[[4-(4-chlorophenyl)pyridin-3-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=NC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 GNHIIXOWHUCNIH-PSXMRANNSA-N 0.000 description 1
- FBPNGFUNOCHSQN-BHVANESWSA-N 4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[4-[[(2s)-4-methyl-1-phenylsulfanylpentan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CSC=3C=CC=CC=3)CC(C)C)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 FBPNGFUNOCHSQN-BHVANESWSA-N 0.000 description 1
- WBTIFBGZPQFNOJ-HSZRJFAPSA-N 4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-n-[6-(4,4-dimethylpiperidin-1-yl)-1,2-benzoxazol-3-yl]-3-nitrobenzenesulfonamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC=1C2=CC=C(C=C2ON=1)N1CCC(C)(C)CC1)[N+]([O-])=O)SC1=CC=CC=C1 WBTIFBGZPQFNOJ-HSZRJFAPSA-N 0.000 description 1
- DJKNRCWSXSZACF-UHFFFAOYSA-N 4-acetamido-n-tert-butylbenzamide Chemical compound CC(=O)NC1=CC=C(C(=O)NC(C)(C)C)C=C1 DJKNRCWSXSZACF-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- VJVPDMJLLXQNCV-MGBGTMOVSA-N 5-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylpyridine-2-carboxamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1N=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 VJVPDMJLLXQNCV-MGBGTMOVSA-N 0.000 description 1
- JBJXHOKIBYXLOH-PGUFJCEWSA-N 5-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylpyridine-2-carboxamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1N=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 JBJXHOKIBYXLOH-PGUFJCEWSA-N 0.000 description 1
- AZNQLJPNUVWYKV-UUWRZZSWSA-N 5-[[4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1C(N)=O)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 AZNQLJPNUVWYKV-UUWRZZSWSA-N 0.000 description 1
- NULBRCAIWYOLPB-UUWRZZSWSA-N 5-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1C(N)=O)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 NULBRCAIWYOLPB-UUWRZZSWSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- SVAGFBGXEWPNJC-SPIKMXEPSA-N 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN SVAGFBGXEWPNJC-SPIKMXEPSA-N 0.000 description 1
- FYSRKRZDBHOFAY-UHFFFAOYSA-N 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(C(N)=O)C=1C1=CC=C(F)C=C1F FYSRKRZDBHOFAY-UHFFFAOYSA-N 0.000 description 1
- GWGXIVXCZZCMDI-UUWRZZSWSA-N 6-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylpyridine-3-carboxamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=NC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 GWGXIVXCZZCMDI-UUWRZZSWSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- LCKAMXRSJOQART-NDEPHWFRSA-N C[C@@H](CSC1=CC=CC=C1)NC(C=CC(S(N)(=O)=O)=C1C(C(C=C2)=CC=C2N2CCN(CC(C=CC=C3)=C3C3=CC=CC=C3)CC2)=O)=C1[N+]([O-])=O Chemical compound C[C@@H](CSC1=CC=CC=C1)NC(C=CC(S(N)(=O)=O)=C1C(C(C=C2)=CC=C2N2CCN(CC(C=CC=C3)=C3C3=CC=CC=C3)CC2)=O)=C1[N+]([O-])=O LCKAMXRSJOQART-NDEPHWFRSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102400000792 Endothelial monocyte-activating polypeptide 2 Human genes 0.000 description 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 229940124137 Interferon gamma antagonist Drugs 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102400000025 Interleukin-1 receptor type 1, soluble form Human genes 0.000 description 1
- 101800000542 Interleukin-1 receptor type 1, soluble form Proteins 0.000 description 1
- 102400000027 Interleukin-1 receptor type 2, soluble form Human genes 0.000 description 1
- 101800001003 Interleukin-1 receptor type 2, soluble form Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
- 101710205006 Interleukin-18-binding protein Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
- 108010016230 MBP-8298 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010005366 RDP 1258 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- POXFJRQAAPDUAC-IRWJKHRASA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-hexylcyclobutane-1-carboxylate Chemical compound C1C(CCCCCC)CC1C(=O)O[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]3[C@@H]2CC1 POXFJRQAAPDUAC-IRWJKHRASA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010004614 allotrap Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- RCTCWZRPYFBGLQ-KVBIMOIYSA-N chembl2105639 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 RCTCWZRPYFBGLQ-KVBIMOIYSA-N 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960000674 colesevelam hydrochloride Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- JMBRWJAVUIITGV-LNNMZZBZSA-N hydrocodone bitartrate Chemical compound [H+].[H+].[H+].[H+].O.O.O.O.O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC JMBRWJAVUIITGV-LNNMZZBZSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002853 midazolam hydrochloride Drugs 0.000 description 1
- PLYSCVSCYOQVRP-UHFFFAOYSA-N midazolam hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F PLYSCVSCYOQVRP-UHFFFAOYSA-N 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- PXJBGEBRSFGPHB-UHFFFAOYSA-N n-(4-cyclohexyloxy-3-nitrophenyl)sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1OC1CCCCC1 PXJBGEBRSFGPHB-UHFFFAOYSA-N 0.000 description 1
- AKPBXEIYIYWEFI-UHFFFAOYSA-N n-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)NS(=O)(=O)C1=CC=CC=C1 AKPBXEIYIYWEFI-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- VLJBDUCKZJWSRI-UHFFFAOYSA-N n-[3-nitro-4-(propan-2-ylamino)phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C1=C([N+]([O-])=O)C(NC(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C1 VLJBDUCKZJWSRI-UHFFFAOYSA-N 0.000 description 1
- MRMMYYPITOQGAT-UHFFFAOYSA-N n-[4-(1-methylpiperidin-4-yl)oxy-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C1[N+]([O-])=O MRMMYYPITOQGAT-UHFFFAOYSA-N 0.000 description 1
- XUGOUBYIQWYWPK-UHFFFAOYSA-N n-[4-(2-bromoethylamino)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C1=C(NCCBr)C([N+](=O)[O-])=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 XUGOUBYIQWYWPK-UHFFFAOYSA-N 0.000 description 1
- NFUPRCQVDJQAFR-UHFFFAOYSA-N n-[4-(2-cyclohexylethoxy)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1OCCC1CCCCC1 NFUPRCQVDJQAFR-UHFFFAOYSA-N 0.000 description 1
- FYQNTAPYEZOSCS-UHFFFAOYSA-N n-[4-(2-cyclohexylethylamino)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCCC1CCCCC1 FYQNTAPYEZOSCS-UHFFFAOYSA-N 0.000 description 1
- FESBUAOKUZDLTH-UHFFFAOYSA-N n-[4-(cyclohexylamino)-3-nitrophenyl]sulfonyl-4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]benzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC3CCCCC3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 FESBUAOKUZDLTH-UHFFFAOYSA-N 0.000 description 1
- XGPYMEUVESFKMU-UHFFFAOYSA-N n-[4-(cyclohexylmethoxy)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1OCC1CCCCC1 XGPYMEUVESFKMU-UHFFFAOYSA-N 0.000 description 1
- URHQLJZDQJSUAP-UHFFFAOYSA-N n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCC1CCCCC1 URHQLJZDQJSUAP-UHFFFAOYSA-N 0.000 description 1
- NDXUHDWDPSNUGR-UHFFFAOYSA-N n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonyl-4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]benzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NCC3CCCCC3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 NDXUHDWDPSNUGR-UHFFFAOYSA-N 0.000 description 1
- HZGLJYAXPIKNTR-UHFFFAOYSA-N n-[4-[(1-benzylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NC(CC1)CCN1CC1=CC=CC=C1 HZGLJYAXPIKNTR-UHFFFAOYSA-N 0.000 description 1
- LWZKYGJBMILTEE-UHFFFAOYSA-N n-[4-[(1-benzylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCC(CC1)CCN1CC1=CC=CC=C1 LWZKYGJBMILTEE-UHFFFAOYSA-N 0.000 description 1
- GYFHNVIGIDUPEU-UHFFFAOYSA-N n-[4-[(1-benzylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCC(CC1)CCN1CC1=CC=CC=C1 GYFHNVIGIDUPEU-UHFFFAOYSA-N 0.000 description 1
- HIRNJNRQLZDFNJ-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-(2-morpholin-4-ylethoxy)-4-[(2-phenylphenyl)methyl]piperidin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCOCC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 HIRNJNRQLZDFNJ-UHFFFAOYSA-N 0.000 description 1
- YQZFFORYDMFRFX-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-piperidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCCC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 YQZFFORYDMFRFX-UHFFFAOYSA-N 0.000 description 1
- ZAWJTLHOGGQBHK-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-pyrrolidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 ZAWJTLHOGGQBHK-UHFFFAOYSA-N 0.000 description 1
- QASBRWUYQCIPKZ-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 QASBRWUYQCIPKZ-UHFFFAOYSA-N 0.000 description 1
- BNZSDVJHVVPOMD-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-[4-(2-morpholin-4-ylethoxy)phenyl]phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(OCCN4CCOCC4)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 BNZSDVJHVVPOMD-UHFFFAOYSA-N 0.000 description 1
- NYLPSJAFGIGUFY-UHFFFAOYSA-N n-[4-[2-(1,3-benzothiazol-2-ylsulfanyl)ethylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(NCCSC=2SC3=CC=CC=C3N=2)C([N+](=O)[O-])=CC=1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=CC=C1 NYLPSJAFGIGUFY-UHFFFAOYSA-N 0.000 description 1
- WRUMDUSJUWWDAO-UHFFFAOYSA-N n-[4-[2-(1,3-benzothiazol-2-ylsulfanyl)ethylamino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(NCCSC=2SC3=CC=CC=C3N=2)C([N+](=O)[O-])=CC=1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 WRUMDUSJUWWDAO-UHFFFAOYSA-N 0.000 description 1
- ZNNCQJIHAXFYLQ-UHFFFAOYSA-N n-[4-[2-(1,3-benzoxazol-2-ylsulfanyl)ethylamino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(NCCSC=2OC3=CC=CC=C3N=2)C([N+](=O)[O-])=CC=1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 ZNNCQJIHAXFYLQ-UHFFFAOYSA-N 0.000 description 1
- ZCDUYURDKBQIJB-DIPNUNPCSA-N n-[4-[[(2r)-1-(benzenesulfonyl)-4-morpholin-4-ylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CS(=O)(=O)C=1C=CC=CC=1)CN1CCOCC1 ZCDUYURDKBQIJB-DIPNUNPCSA-N 0.000 description 1
- YTPGCVKEAKRXKE-KXQOOQHDSA-N n-[4-[[(2r)-4-(1,3-benzodioxol-5-ylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCNC=1C=C2OCOC2=CC=1)NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 YTPGCVKEAKRXKE-KXQOOQHDSA-N 0.000 description 1
- PTWSLRUKJPITFD-LDLOPFEMSA-N n-[4-[[(2r)-4-(4-acetylpiperazin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1CN(C(=O)C)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 PTWSLRUKJPITFD-LDLOPFEMSA-N 0.000 description 1
- XAZCVBWIOBTULF-DYVVHTQJSA-N n-[4-[[(2r)-4-(7-azabicyclo[2.2.1]heptan-7-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN1C2CCC1CC2)NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)SC1=CC=CC=C1 XAZCVBWIOBTULF-DYVVHTQJSA-N 0.000 description 1
- IRNVKVFPXDNFOW-MGBGTMOVSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-3,5-difluoro-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=C(F)C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=C(F)C=1)[N+]([O-])=O)SC1=CC=CC=C1 IRNVKVFPXDNFOW-MGBGTMOVSA-N 0.000 description 1
- UQZHAQATWBSHTI-UUWRZZSWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-3-fluoro-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=C(F)C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=1)[N+]([O-])=O)SC1=CC=CC=C1 UQZHAQATWBSHTI-UUWRZZSWSA-N 0.000 description 1
- ATBNCVGFQYBJBN-MGBGTMOVSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-morpholin-4-ylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)N2CCOCC2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ATBNCVGFQYBJBN-MGBGTMOVSA-N 0.000 description 1
- MWQLXEGHOOUBPU-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical group C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 MWQLXEGHOOUBPU-PGUFJCEWSA-N 0.000 description 1
- GMHRNZOPJUSQHA-JGCGQSQUSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-propan-2-ylsulfanylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound CC(C)SC1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 GMHRNZOPJUSQHA-JGCGQSQUSA-N 0.000 description 1
- YVZYKXDSCCZVEP-PSXMRANNSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C=C(C=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 YVZYKXDSCCZVEP-PSXMRANNSA-N 0.000 description 1
- LBFKZYARWPEEIA-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-fluorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(F)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LBFKZYARWPEEIA-PGUFJCEWSA-N 0.000 description 1
- WKHJNMJLJPZLRD-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methoxyphenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(OC)=CC=C1C(CCCC1)=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 WKHJNMJLJPZLRD-PGUFJCEWSA-N 0.000 description 1
- NPQDDTAZBMDBEF-UUWRZZSWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methoxyphenyl)pyridin-3-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(OC)=CC=C1C1=NC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 NPQDDTAZBMDBEF-UUWRZZSWSA-N 0.000 description 1
- DVXDMDAYNGTNIV-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methylsulfanylphenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(SC)=CC=C1C(CCCC1)=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 DVXDMDAYNGTNIV-PGUFJCEWSA-N 0.000 description 1
- WTFYMODLJDZGSV-UUWRZZSWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methylsulfanylphenyl)pyridin-3-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(SC)=CC=C1C1=NC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 WTFYMODLJDZGSV-UUWRZZSWSA-N 0.000 description 1
- KYLBZYBWVQZUGB-UUWRZZSWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methylsulfonylphenyl)pyridin-3-yl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=NC=CC=2)C=2C=CC(=CC=2)S(C)(=O)=O)CC1)[N+]([O-])=O)SC1=CC=CC=C1 KYLBZYBWVQZUGB-UUWRZZSWSA-N 0.000 description 1
- ZWPBWNPQVAKMEB-JGCGQSQUSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(5,5-dimethyl-2-oxo-1,3-oxazolidin-3-yl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)N2C(OC(C)(C)C2)=O)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ZWPBWNPQVAKMEB-JGCGQSQUSA-N 0.000 description 1
- WTWLLVXVWKNXCN-MGBGTMOVSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(5-methylthiophen-2-yl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2SC(C)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 WTWLLVXVWKNXCN-MGBGTMOVSA-N 0.000 description 1
- GAMZQJKVODJWHK-JGCGQSQUSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(propan-2-ylamino)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound CC(C)NC1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 GAMZQJKVODJWHK-JGCGQSQUSA-N 0.000 description 1
- GOUUFVVBOJUOIM-PSXMRANNSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]benzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 GOUUFVVBOJUOIM-PSXMRANNSA-N 0.000 description 1
- DFEGKCOCDVJOAB-VZUYHUTRSA-N n-[4-[[(2r)-4-(dimethylamino)-2-methyl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@](C)(CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 DFEGKCOCDVJOAB-VZUYHUTRSA-N 0.000 description 1
- YNYWGKGNFUXVSI-FZNHDDJXSA-N n-[4-[[(2r)-4-[(3r)-3-aminopyrrolidin-1-yl]-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1[C@H](N)CCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 YNYWGKGNFUXVSI-FZNHDDJXSA-N 0.000 description 1
- GLEBVWRDBFWHES-MGBGTMOVSA-N n-[4-[[(2r)-4-amino-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 GLEBVWRDBFWHES-MGBGTMOVSA-N 0.000 description 1
- QGDBAWRHDYBDOG-PSXMRANNSA-N n-[4-[[(2r)-4-imidazol-1-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)CSC=1C=CC=CC=1)CN1C=CN=C1 QGDBAWRHDYBDOG-PSXMRANNSA-N 0.000 description 1
- KOVWUSMJBCNXMH-DIPNUNPCSA-N n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 KOVWUSMJBCNXMH-DIPNUNPCSA-N 0.000 description 1
- CQJPPAPFLLSQLE-KXQOOQHDSA-N n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C=C(C=CC=2)C=2C=CC=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 CQJPPAPFLLSQLE-KXQOOQHDSA-N 0.000 description 1
- QTLBDSMTUSGNOA-PGUFJCEWSA-N n-[4-[[(2r)-6-(carbamoylamino)-1-phenylsulfanylhexan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCCCNC(=O)N)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 QTLBDSMTUSGNOA-PGUFJCEWSA-N 0.000 description 1
- DFEGKCOCDVJOAB-QLKFWGTOSA-N n-[4-[[(2s)-4-(dimethylamino)-2-methyl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@](C)(CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 DFEGKCOCDVJOAB-QLKFWGTOSA-N 0.000 description 1
- KOVWUSMJBCNXMH-QNGWXLTQSA-N n-[4-[[(2s)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 KOVWUSMJBCNXMH-QNGWXLTQSA-N 0.000 description 1
- YAHSMMRTGVSUCR-UHFFFAOYSA-N n-[4-[[1,2-diphenylethyl(methyl)carbamoyl]-methylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C(=O)N(C)C(C=1C=CC=CC=1)CC1=CC=CC=C1 YAHSMMRTGVSUCR-UHFFFAOYSA-N 0.000 description 1
- ADTHIDLKHDPOKG-UHFFFAOYSA-N n-[4-[[1-(benzenesulfonyl)-2-methylpropan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CS(=O)(=O)C1=CC=CC=C1 ADTHIDLKHDPOKG-UHFFFAOYSA-N 0.000 description 1
- XYBTZOQHMHGKHU-UHFFFAOYSA-N n-[4-[[1-[(2-methylfuran-3-yl)sulfanylmethyl]cyclopentyl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound O1C=CC(SCC2(CCCC2)NC=2C(=CC(=CC=2)S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)[N+]([O-])=O)=C1C XYBTZOQHMHGKHU-UHFFFAOYSA-N 0.000 description 1
- UXAQLSDITLOXLS-UHFFFAOYSA-N n-[4-[[benzhydryl(methyl)carbamoyl]-methylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C(=O)N(C)C(C=1C=CC=CC=1)C1=CC=CC=C1 UXAQLSDITLOXLS-UHFFFAOYSA-N 0.000 description 1
- XXEKQNYQQXHBEC-UHFFFAOYSA-N n-[4-[cyclohexyl(methyl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C1CCCCC1 XXEKQNYQQXHBEC-UHFFFAOYSA-N 0.000 description 1
- UZQBSVSZSYCGMH-UHFFFAOYSA-N n-[4-[cyclohexylmethyl(methyl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)CC1CCCCC1 UZQBSVSZSYCGMH-UHFFFAOYSA-N 0.000 description 1
- KKPWDZGYFMCFCT-UHFFFAOYSA-N n-[4-[methyl-[methyl-(2-morpholin-4-yl-1-phenylethyl)carbamoyl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C(=O)N(C)C(C=1C=CC=CC=1)CN1CCOCC1 KKPWDZGYFMCFCT-UHFFFAOYSA-N 0.000 description 1
- QULHVPMNZBNJDM-UHFFFAOYSA-N n-[4-[methyl-[methyl-[4-(trifluoromethoxy)phenyl]carbamoyl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N(C)C(=O)N(C)C(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=CC=C1 QULHVPMNZBNJDM-UHFFFAOYSA-N 0.000 description 1
- VAEBZFQSQVRGNP-RUZDIDTESA-N n-[6-(4,4-dimethylpiperidin-1-yl)-1,2-benzoxazol-3-yl]-4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzenesulfonamide Chemical compound C1CC(C)(C)CCN1C1=CC=C(C(NS(=O)(=O)C=2C=C(C(N[C@H](CCN3CCOCC3)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)=NO2)C2=C1 VAEBZFQSQVRGNP-RUZDIDTESA-N 0.000 description 1
- YIRYUYATLQZEHG-DIPNUNPCSA-N n-[6-[4-(3,3-diphenylprop-1-en-2-yl)piperazin-1-yl]-1,2-benzoxazol-3-yl]-4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzenesulfonamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC=1C2=CC=C(C=C2ON=1)N1CCN(CC1)C(=C)C(C=1C=CC=CC=1)C=1C=CC=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 YIRYUYATLQZEHG-DIPNUNPCSA-N 0.000 description 1
- SAJVDLWHWUGIFQ-UHFFFAOYSA-N n-[6-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-1-methylindazol-3-yl]-4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrobenzenesulfonamide Chemical compound C12=CC=C(N3CCN(CC=4C(=CC=CC=4)C=4C=CC(Cl)=CC=4)CC3)C=C2N(C)N=C1NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(C)(C)CSC1=CC=CC=C1 SAJVDLWHWUGIFQ-UHFFFAOYSA-N 0.000 description 1
- IMTXKXYGDBHHKK-PGUFJCEWSA-N n-[6-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-1h-indazol-3-yl]-4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzenesulfonamide Chemical compound C([C@@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC=1C2=CC=C(C=C2NN=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 IMTXKXYGDBHHKK-PGUFJCEWSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920003175 pectinic acid Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960003107 tramadol hydrochloride Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98847907P | 2007-11-16 | 2007-11-16 | |
| US60/988,479 | 2007-11-16 | ||
| PCT/US2008/083478 WO2009064938A1 (en) | 2007-11-16 | 2008-11-14 | Method of treating arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013232754A Division JP5667684B2 (ja) | 2007-11-16 | 2013-11-11 | 関節炎の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503199A JP2011503199A (ja) | 2011-01-27 |
| JP2011503199A5 JP2011503199A5 (enExample) | 2012-01-05 |
| JP5450434B2 true JP5450434B2 (ja) | 2014-03-26 |
Family
ID=40291332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534194A Expired - Fee Related JP5450434B2 (ja) | 2007-11-16 | 2008-11-14 | 関節炎の治療方法 |
| JP2013232754A Expired - Fee Related JP5667684B2 (ja) | 2007-11-16 | 2013-11-11 | 関節炎の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013232754A Expired - Fee Related JP5667684B2 (ja) | 2007-11-16 | 2013-11-11 | 関節炎の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20090176785A1 (enExample) |
| EP (1) | EP2231159A1 (enExample) |
| JP (2) | JP5450434B2 (enExample) |
| KR (1) | KR101585848B1 (enExample) |
| CN (1) | CN101969951B (enExample) |
| AU (1) | AU2008322595B2 (enExample) |
| CA (1) | CA2705294C (enExample) |
| DO (1) | DOP2013000169A (enExample) |
| IL (2) | IL205501A (enExample) |
| MX (1) | MX2010005395A (enExample) |
| NZ (2) | NZ601350A (enExample) |
| RU (2) | RU2526201C2 (enExample) |
| WO (1) | WO2009064938A1 (enExample) |
| ZA (1) | ZA201003434B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| DK2550258T3 (en) | 2010-03-25 | 2015-12-07 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PH12013501006A1 (en) | 2010-11-23 | 2022-03-30 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2948287T3 (es) | 2017-08-23 | 2023-09-07 | Guangzhou Lupeng Pharmaceutical Company Ltd | Derivados heterocíclicos condensados como inhibidores de Bcl-2 para el tratamiento de enfermedades neoplásicas |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| PH12022551091A1 (en) | 2019-11-05 | 2024-06-24 | Abbvie Deutschland | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| AU2021228622A1 (en) | 2020-02-24 | 2022-10-13 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Hot melt extruded solid dispersions containing a BCL2 inhibitor |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| WO1997013751A1 (en) * | 1995-10-10 | 1997-04-17 | Pfizer Inc. | Indole carbamates as leukotriene antagonists |
| CN1425004A (zh) * | 2000-03-21 | 2003-06-18 | 宝洁公司 | 含杂环侧链的n－取代的金属蛋白酶抑制剂 |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| JP2007500703A (ja) * | 2003-07-28 | 2007-01-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用 |
| EP1663979B1 (en) * | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| ES2257929B1 (es) * | 2004-07-16 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. |
| TWI337608B (en) * | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| US20060276464A1 (en) * | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
-
2008
- 2008-11-14 KR KR1020107013163A patent/KR101585848B1/ko not_active Expired - Fee Related
- 2008-11-14 JP JP2010534194A patent/JP5450434B2/ja not_active Expired - Fee Related
- 2008-11-14 RU RU2012143212/15A patent/RU2526201C2/ru not_active IP Right Cessation
- 2008-11-14 AU AU2008322595A patent/AU2008322595B2/en not_active Ceased
- 2008-11-14 WO PCT/US2008/083478 patent/WO2009064938A1/en not_active Ceased
- 2008-11-14 US US12/270,987 patent/US20090176785A1/en not_active Abandoned
- 2008-11-14 NZ NZ601350A patent/NZ601350A/xx not_active IP Right Cessation
- 2008-11-14 CA CA2705294A patent/CA2705294C/en not_active Expired - Fee Related
- 2008-11-14 EP EP08850262A patent/EP2231159A1/en not_active Withdrawn
- 2008-11-14 MX MX2010005395A patent/MX2010005395A/es active IP Right Grant
- 2008-11-14 CN CN2008801242231A patent/CN101969951B/zh not_active Expired - Fee Related
- 2008-11-14 RU RU2010123796/15A patent/RU2472509C2/ru not_active IP Right Cessation
- 2008-11-14 NZ NZ585085A patent/NZ585085A/xx not_active IP Right Cessation
-
2010
- 2010-05-02 IL IL205501A patent/IL205501A/en not_active IP Right Cessation
- 2010-05-14 ZA ZA2010/03434A patent/ZA201003434B/en unknown
-
2013
- 2013-07-23 DO DO2013000169A patent/DOP2013000169A/es unknown
- 2013-07-24 IL IL227641A patent/IL227641A0/en unknown
- 2013-11-11 JP JP2013232754A patent/JP5667684B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-17 US US14/972,429 patent/US20160101109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL205501A0 (en) | 2010-12-30 |
| KR101585848B1 (ko) | 2016-01-15 |
| NZ585085A (en) | 2012-08-31 |
| MX2010005395A (es) | 2010-06-02 |
| CN101969951A (zh) | 2011-02-09 |
| CN101969951B (zh) | 2012-10-31 |
| JP2014065716A (ja) | 2014-04-17 |
| US20090176785A1 (en) | 2009-07-09 |
| NZ601350A (en) | 2013-08-30 |
| WO2009064938A1 (en) | 2009-05-22 |
| KR20100099172A (ko) | 2010-09-10 |
| RU2472509C2 (ru) | 2013-01-20 |
| ZA201003434B (en) | 2011-10-26 |
| JP2011503199A (ja) | 2011-01-27 |
| WO2009064938A9 (en) | 2009-08-06 |
| RU2010123796A (ru) | 2011-12-27 |
| CA2705294C (en) | 2016-05-17 |
| CA2705294A1 (en) | 2009-05-22 |
| RU2526201C2 (ru) | 2014-08-20 |
| EP2231159A1 (en) | 2010-09-29 |
| US20160101109A1 (en) | 2016-04-14 |
| IL205501A (en) | 2013-08-29 |
| AU2008322595A1 (en) | 2009-05-22 |
| RU2012143212A (ru) | 2014-04-20 |
| JP5667684B2 (ja) | 2015-02-12 |
| IL227641A0 (en) | 2013-09-30 |
| AU2008322595B2 (en) | 2014-01-30 |
| DOP2013000169A (es) | 2013-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| RU2012127306A (ru) | Новые трициклические соединения | |
| CN101808515A (zh) | 作为趋化因子受体拮抗剂的八氢并环戊二烯化合物 | |
| RU2010153582A (ru) | Новые трициклические соединения | |
| JP2005538099A5 (enExample) | ||
| EA032028B1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| RU2005135958A (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5, 8, 14-триазатетрацикло[10.3.1.02,11.04,9]-гексадека-2( 11 ), 3,5,7,9-пентаена | |
| JP2018507167A5 (enExample) | ||
| JP7161474B2 (ja) | ブラジキニンｂ１受容体の拮抗薬としてのカルボン酸芳香族アミド類 | |
| RU2019104609A (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2 | |
| JP2021001221A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| US20230405015A1 (en) | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma | |
| JP2010513489A5 (enExample) | ||
| RU2011139287A (ru) | Оксииндольные производные, обладающие агонистической активностью в отношении мотилинового рецептора | |
| JP2002536442A5 (enExample) | ||
| RU2001121989A (ru) | Производные (1-фенацил-3-фенил-3-пиперидилэтил)пиперидина, способы их получения и содержащие их фармацевтические композиции | |
| TW202327611A (zh) | 使用ｂｔｋ抑制劑和ｐ１３激酶抑制劑的組合治療癌症之方法 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| RU2024113309A (ru) | Производные пирролидина в качестве ингибиторов ddr | |
| WO2025072539A1 (en) | Amino acid compounds with nitrogen linkers and uses thereof | |
| MXPA06010598A (es) | Composicion farmaceutica de (+) -eritro-mefloquina y su uso. | |
| NZ614347B2 (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130822 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131111 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131225 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |